The emergence of GLP-1 agonists in the UK presents significant
opportunity – and potential threat – to retail and
consumer goods organisations.
Matt Clark, Partner & Managing Director at AlixPartners, and
Alex Gourlay, Executive Chair at Holland & Barrett, discuss the
potential implications for these sectors, the strategies to
consider to harness this disruptive change, and the potential
evolution in consumer behaviours as the pace of adoption
accelerates.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
